Awareness of the risk factors for residual apnoeic–hypopnoeic events can improve the timely delivery of personalized care for patients with obstructive sleep apnoea (OSA), including the type of positive airway pressure (PAP) therapy, attention to comorbidities and choice of interface, a study has shown.
Airflow obstruction and lower lung volumes appear to increase the risk of endothelial dysfunction in middle-aged women, suggests a recent study. On the other hand, the evidence for such association in men is weaker.
Chronic kidney disease patients referred for right heart catheterization commonly have pulmonary hypertension (PH), with the combination of pre- and postcapillary PH subtypes associated with worst survival, a study reports.
Persistent or chronic viral infections, such as Epstein-Barr virus and cytomegalovirus, may promote the development, but not exacerbation, of idiopathic pulmonary fibrosis, according to the results of a meta-analysis.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Exposure to inhaled corticosteroid therapy for chronic obstructive pulmonary disease (COPD) in the long term may be detrimental to patients, being associated with elevated risks of diabetes, its progression and osteoporosis, as shown in a study.
An antimicrobial stewardship approach of de-escalating from combination therapy with beta-lactam plus macrolide to beta-lactam monotherapy in the management of patients with severe community-acquired pneumonia (CAP) and a negative BioFire FilmArray Respiratory Panel 2 polymerase chain reaction (BioFire PCR) result is reasonable and does not lead to increased in-hospital mortality, according to a recent study.
In patients with chronic respiratory failure managed with domiciliary noninvasive ventilation (NIV), a single night of intelligent volume-assured pressure support (iVAPS) with an automatically adjusting expiratory positive airway pressure (AutoEPAP) is noninferior to that with manual EPAP titration, a recent study has shown.
First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.